Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial ...

11 September 2026 · By · Wire by Fusion42

Published

11 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at nasdaq.com →

◆ Verified

Fusion42 · 11 September 2026 · Fusion42 review

Outlook Therapeutics CEO Bob Jahr discussed the FDA approval of LYTENAVA™, the only FDA-approved ophthalmic bevacizumab formulation for wet AMD, and the company's plans for US commercial launch targeting significant market penetration and over $500 million in annual sales by 2030.

This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 10 Sep 2026 and 11 Sep 2026.

◆ ◆ The Wire takeaway

Your retinal drug venture must now prepare for new US competition as LYTENAVA turns off-label bevacizumab use into a regulated, approved alternative undercutting current practice. Rapidly align with physicians and payers who will shift preference to approved treatments.

◆ Coverage

3 sources · first reported 10 Sep 2026 · latest 11 Sep 2026

◆ Related on Wire

◆ Topics

Medtechfda-approvalophthalmic-drugwet-amdcommercial-launchbiopharma